Sk Biopharmaceuticals Co Ltd (326030) - Net Assets
Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has net assets worth ₩826.27 Billion KRW (≈ $559.95 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.20 Trillion ≈ $812.08 Million USD) and total liabilities (₩372.04 Billion ≈ $252.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 326030 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩826.27 Billion |
| % of Total Assets | 68.95% |
| Annual Growth Rate | 21.09% |
| 5-Year Change | 86.02% |
| 10-Year Change | N/A |
| Growth Volatility | 60.27 |
Sk Biopharmaceuticals Co Ltd - Net Assets Trend (2016–2025)
This chart illustrates how Sk Biopharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. See how many days can Sk Biopharmaceuticals Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Sk Biopharmaceuticals Co Ltd (2016–2025)
The table below shows the annual net assets of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. For live valuation and market cap data, see Sk Biopharmaceuticals Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩826.27 Billion ≈ $559.95 Million |
+43.95% |
| 2024-12-31 | ₩573.98 Billion ≈ $388.98 Million |
+78.84% |
| 2023-12-31 | ₩320.95 Billion ≈ $217.50 Million |
+1.39% |
| 2022-12-31 | ₩316.56 Billion ≈ $214.53 Million |
-28.73% |
| 2021-12-31 | ₩444.19 Billion ≈ $301.02 Million |
+17.18% |
| 2020-12-31 | ₩379.07 Billion ≈ $256.89 Million |
+3010.24% |
| 2019-12-31 | ₩-13.03 Billion ≈ $-8.83 Million |
-122.22% |
| 2018-12-31 | ₩58.63 Billion ≈ $39.73 Million |
+24.10% |
| 2017-12-31 | ₩47.24 Billion ≈ $32.02 Million |
-68.01% |
| 2016-12-31 | ₩147.69 Billion ≈ $100.09 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sk Biopharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16487055432000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩1.17 Trillion | 143.56% |
| Total Equity | ₩813.04 Billion | 100.00% |
Sk Biopharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enagás S.A.
MC:ENG
|
$4.62 Billion |
|
LG Display Co Ltd
NYSE:LPL
|
$4.62 Billion |
|
Bumrungrad Hospital PCL
BK:BH
|
$4.62 Billion |
|
FPT Corp
VN:FPT
|
$4.63 Billion |
|
Jiangsu Guoxin Corp Ltd
SHE:002608
|
$4.62 Billion |
|
SCOR.ADR1/10/EO-78769723
F:SDRB
|
$4.62 Billion |
|
Axiata Group Bhd
KLSE:6888
|
$4.61 Billion |
|
Addsino Co Ltd
SHE:000547
|
$4.61 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sk Biopharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 546,273,129,340 to 813,035,724,860, a change of 266,762,595,520 (48.8%).
- Net income of 266,950,497,800 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩266.95 Billion | +32.83% |
| Other Changes | ₩-187.90 Million | -0.02% |
| Total Change | ₩- | 48.83% |
Book Value vs Market Value Analysis
This analysis compares Sk Biopharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 155.76x to 8.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩558.57 | ₩87000.00 | x |
| 2018-12-31 | ₩693.19 | ₩87000.00 | x |
| 2019-12-31 | ₩-154.00 | ₩87000.00 | x |
| 2020-12-31 | ₩4840.39 | ₩87000.00 | x |
| 2021-12-31 | ₩5671.93 | ₩87000.00 | x |
| 2022-12-31 | ₩4042.23 | ₩87000.00 | x |
| 2023-12-31 | ₩3622.46 | ₩87000.00 | x |
| 2024-12-31 | ₩6975.49 | ₩87000.00 | x |
| 2025-12-31 | ₩10381.84 | ₩87000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sk Biopharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 32.83%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 37.77%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.47x
- Recent ROE (32.83%) is above the historical average (-49.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -20.56% | -33.76% | 0.46x | 1.31x | ₩-45.13 Billion |
| 2017 | -206.70% | -114.46% | 0.87x | 2.08x | ₩-102.37 Billion |
| 2018 | -235.54% | -12568.64% | 0.01x | 1.63x | ₩-143.96 Billion |
| 2019 | 0.00% | -57.75% | 0.89x | 0.00x | ₩-70.22 Billion |
| 2020 | -65.27% | -951.63% | 0.05x | 1.32x | ₩-285.32 Billion |
| 2021 | 14.60% | 15.49% | 0.65x | 1.45x | ₩20.43 Billion |
| 2022 | -44.05% | -56.64% | 0.37x | 2.10x | ₩-171.09 Billion |
| 2023 | -11.59% | -9.27% | 0.49x | 2.55x | ₩-61.25 Billion |
| 2024 | 44.07% | 43.96% | 0.53x | 1.90x | ₩186.11 Billion |
| 2025 | 32.83% | 37.77% | 0.59x | 1.47x | ₩185.65 Billion |
Industry Comparison
This section compares Sk Biopharmaceuticals Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $220,072,755,126
- Average return on equity (ROE) among peers: -0.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sk Biopharmaceuticals Co Ltd (326030) | ₩826.27 Billion | -20.56% | 0.45x | $4.62 Billion |
| ORIENTBIO Inc. (002630) | $83.19 Billion | 41.11% | 0.26x | $69.43 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $325.83 Million |
| Green Cross Holdings Preference Shares (005257) | $1.31 Trillion | 5.00% | 0.57x | $3.22 Million |
| Pharmicell (005690) | $94.60 Billion | -0.72% | 0.08x | $546.93 Million |
| GeneOne Life Science Inc (011000) | $35.85 Billion | -43.51% | 0.83x | $42.64 Million |
| HLB Co. Ltd (028300) | $174.68 Billion | 14.51% | 0.74x | $4.28 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $37.00 Billion | 2.34% | 0.69x | $16.46 Million |
| Seoulin Bioscience Co.Ltd (038070) | $83.89 Billion | 3.47% | 0.21x | $29.61 Million |
| Hyundai Bioscience Co. Ltd (048410) | $18.21 Billion | -44.31% | 1.93x | $574.04 Million |
| iNtRON Biotechnology Inc (048530) | $83.77 Billion | -3.09% | 0.03x | $56.99 Million |
About Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more